^
Association details:
| Biomarker: | PRDX1 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | entospletinib (GS-9973) (SYK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Single cell and bulk transcriptome analysis identified oxidative stress response-related features of Hepatocellular Carcinoma
Published date:
09/28/2023
Excerpt:
From the results, HCC patients in the high PRDX1 expression group exhibited greater sensitivity to twelve drugs, including Sorafenib (multi-kinase inhibitor), Linsitinib (IGF-1R inhibitor), JAK inhibitor (AZ960), ERK inhibitor (ERK 2440), Mitochondrial inhibitor (Dihydrorotenone), IKK inhibitor (BMS-345541), IRAK4 inhibitor (IRAK4_4710), SYK inhibitor (Entospletinib), TGF-β Receptor I/II inhibitor (LY2109761), MCL-1 inhibitor (AZD5991), KRAS (G12C) inhibitor, and I−BET inhibitor (I-BET-762), than patients with low PRDX1 expression group.
DOI:
https://doi.org/10.3389/fcell.2023.1191074
